PERTH, Australia – Investment in research and development fell sharply in the last decade in Australia, and the government can play an important role to improve framework conditions that support innovation, according to the Australian Innovation System Report 2017.
PERTH, Australia – Belgium's Tigenix NV licensed intellectual property from Australian stem cell company Mesoblast Ltd. the same day it announced approval of the EU's first allogeneic stem cell therapy. The deal supported Tigenix's global commercialization of the adipose-derived mesenchymal stem cell product, Cx601, for the local treatment of fistulae for Crohn's disease. (See BioWorld, Dec. 18, 2017.)
PERTH, Australia – Belgium’s Tigenix NV licensed intellectual property from Australian stem cell company Mesoblast Ltd. the same day it announced approval of the EU’s first allogeneic stem cell therapy.
PERTH, Australia – Investment in research and development fell sharply in the last decade in Australia, and the government can play an important role to improve framework conditions that support innovation, according to the Australian Innovation System Report 2017.
PERTH, Australia – IP Australia released its final recommendations on five separate intellectual property policy amendments put forward by the Productivity Commission that are expected to make their way through Parliament in 2018.
PERTH, Australia – IP Australia released its final recommendations on five separate intellectual property policy amendments put forward by the Productivity Commission that are expected to make their way through Parliament in 2018.
PERTH, Australia – Implementing drug and device regulatory reforms that were begun in 2017 will continue to be top priorities for Australia's Therapeutic Goods Administration, according to its newly published TGA Business Plan 2017-18.
PERTH, Australia – Melbourne-based Starpharma Ltd. submitted a rolling submission of its Vivagel new drug application (NDA) to the FDA for preventing and treating recurrent bacterial vaginosis (rBV). With that submission, the biotech company joins a very limited club of Australian biotechs to bring their products all the way through to registration.
